Angela Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Angela Kim has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Jack F. Shern
Pediatric Oncology Branch, National Cancer Institute, Bethesda, USA
83 shared publications - Katie E. Hebron
Laboratory of Cell and Developmental Signaling, National Cancer Institute at Frederick, National Institutes of Health, Frederick, MD 21701, USA
75 shared publications - Marielle E. Yohe
Laboratory of Cell and Developmental Signaling, Center for Cancer Research, National Cancer Institute, NIH, Frederick, MD 21701, USA
75 shared publications - Haiyan Lei
Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
74 shared publications - Olivia L. Perkins
Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
74 shared publications - Frederic G. Barr
Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892
57 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
NAPRT-deficient RMS models are sensitive to FK866 and cannot be rescued with NA
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
NAPRT-deficient RMS models are sensitive to FK866 and cannot be rescued with NA
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Functional validation of single-cell clones of CRISPR/Cas9 ribonucleoprotein (RNP) based NAPRT knock-out model
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Functional validation of single-cell clones of CRISPR/Cas9 ribonucleoprotein (RNP) based NAPRT knock-out model
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Figure 2. NAPRT-deficient RMS models are not able to utilize NA to rescue cell viability
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Figure 2. NAPRT-deficient RMS models are not able to utilize NA to rescue cell viability
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Figure 3. Generation of plasmid based NAPRT overexpressing isogenic model.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Figure 3. Generation of plasmid based NAPRT overexpressing isogenic model.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Figure 7. Clinical Correlates of NAPRT Expression in RMS patient samples.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Figure 7. Clinical Correlates of NAPRT Expression in RMS patient samples.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Tables with list of antibodies and description of TMAs
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Tables with list of antibodies and description of TMAs
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Figure 5. Induction of apoptosis in RMS models with OT-82 treatment
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Figure 5. Induction of apoptosis in RMS models with OT-82 treatment
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Figure 6. Tumor volumes in RMS isogenic models after OT-82 treatment.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Figure 6. Tumor volumes in RMS isogenic models after OT-82 treatment.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 6 from ASAP1 and ARF1 Regulate Myogenic Differentiation in Rhabdomyosarcoma by Modulating TAZ Activity
Knockdown verification and representative images for ASAP1/WWTR1 knockdown
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 6 from ASAP1 and ARF1 Regulate Myogenic Differentiation in Rhabdomyosarcoma by Modulating TAZ Activity
Knockdown verification and representative images for ASAP1/WWTR1 knockdown